By Douglas Feil, Chief Program Officer, National Breast Cancer Foundation (NBCF) In recent years, glucagon-like peptide-1 (GLP-1)...
Patient Advocacy and Support
NEW YORK, NY — As the sun sets on October 13, 2026, the global skyline will undergo...
The landscape of HER2-positive metastatic breast cancer (MBC) treatment has reached a significant milestone. The U.S. Food...
TORONTO — As the landscape of oncology shifts from a singular focus on acute treatment toward a...
By Douglas Feil, NBCF Chief Program Officer The landscape of medical treatment is constantly evolving, and the...
NEW YORK, NY — As the sun sets on October 13, 2026, the global architectural landscape will...
The landscape of oncology is shifting toward more personalized, durable, and effective treatment regimens, particularly for those...
TORONTO, ON — As medical advancements continue to improve survival rates for breast cancer, the focus of...
Introduction The landscape of metabolic health management has been significantly reshaped by the emergence of Glucagon-Like Peptide-1...
NEW YORK, NY — As the sun sets on October 13, 2026, a synchronized wave of teal,...
